NasdaqCM · Biotechnology

Whitehawk Therapeutics (WHWK)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+58.6%

$7.50 average target

$4.73-0.10 (-2.1%)Latest market snapshot · Yahoo Finance

Market cap$269.7M

Cash$190.0M

Quarterly burn$14.5M

Pipeline assets3

Short float12.5%

Latest coverage

News & Press Releases

External sources

Aug 6, 2026

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsPR Newswire

Aug 4, 2026

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationGlobeNewswire

Jul 21, 2026

Akari Therapeutics, Whitehawk Therapeutics Collaborate to Develop ADC Cancer TreatmentsMT Newswires

Continue with BioPharma ProUnlock 5 more recent stories and press releases.

Unlock Pro

Company profile

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.